Recursion Pharmaceuticals Future Growth
Future criteria checks 2/6
Recursion Pharmaceuticals's earnings are forecast to decline at 13.5% per annum while its annual revenue is expected to grow at 30.2% per year. EPS is expected to decline by 3.5% per annum. Return on equity is forecast to be -205.5% in 3 years.
Key information
-13.5%
Earnings growth rate
-3.5%
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | 30.2% |
| Future return on equity | -205.5% |
| Analyst coverage | Good |
| Last updated | 22 Mar 2024 |
Recent future growth updates
Recent updates
Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31
Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Recursion Pharmaceuticals: Destination Unknown
Sep 20Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth
Jul 25Recursion gets European orphan drug designation for its REC-4881 inhibitor
Jul 21These Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Sales Are Under Threat
May 16Recursion Pharmaceuticals, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 151 | -398 | -271 | -255 | 2 |
| 12/31/2025 | 61 | -481 | -414 | -368 | 6 |
| 12/31/2024 | 54 | -411 | -377 | -364 | 6 |
| 12/31/2023 | 45 | -328 | -300 | -288 | N/A |
| 9/30/2023 | 47 | -293 | -277 | -258 | N/A |
| 6/30/2023 | 50 | -260 | -266 | -240 | N/A |
| 3/31/2023 | 47 | -249 | -273 | -234 | N/A |
| 12/31/2022 | 40 | -239 | -121 | -84 | N/A |
| 9/30/2022 | 29 | -247 | -134 | -100 | N/A |
| 6/30/2022 | 18 | -234 | -113 | -78 | N/A |
| 3/31/2022 | 13 | -212 | -75 | -50 | N/A |
| 12/31/2021 | 10 | -186 | -198 | -159 | N/A |
| 9/30/2021 | 10 | -147 | -129 | -89 | N/A |
| 6/30/2021 | 9 | -124 | -106 | -75 | N/A |
| 3/31/2021 | 6 | -99 | -84 | -58 | N/A |
| 12/31/2020 | 4 | -87 | -52 | -45 | N/A |
| 12/31/2019 | 2 | -62 | -61 | -57 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RXRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RXRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RXRX's revenue (30.2% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: RXRX's revenue (30.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RXRX is forecast to be unprofitable in 3 years.